We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Microbia Announces Second Collaboration Agreement with Ranbaxy Laboratories

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Microbia Announces Second Collaboration Agreement with Ranbaxy Laboratories "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Microbia, Inc. have announced that its Precision Engineering™ business unit has entered into a research collaboration with Ranbaxy Laboratories to lower the cost of a biomanufacturing process under development by Ranbaxy.

The goal is to achieve a greater than 100 percent productivity improvement in the precommercial biomanufacturing of an undisclosed pharmaceutical product.

Microbia will undertake strain engineering and laboratory-scale testing. Ranbaxy assumes responsibility for optimizing processes and validating product specification acceptability.

Under the agreement, Ranbaxy will fund Microbia's research and development and will make payments based on the achievement of development milestones. Financial terms were not disclosed.

This is the second agreement between the two companies, following a successful collaboration to apply Precision Engineering™ to generate higher yields in a Ranbaxy biomanufacturing process for a statin.

Ranbaxy has since advanced the improved strain into commercial manufacturing. The two companies have collaborated to improve biomanufacturing processes since February 2003.